Remove Blog Remove Diagnose Remove Manufacturing Remove Patients
article thumbnail

FDA Redux? CDRH Policy and EUA Templates for Monkeypox Tests Following Public Health Emergency Declaration Mirror FDA’s COVID-19 Approach

FDA Law

This led to delays in releasing a uniform policy and templates for COVID-19, as well as many other problems (see blog post chronicling some of the challenges here ). On the same day, September 7, CDRH published a policy for monkeypox tests. We note that this policy defines an “experienced developer” more narrowly than the COVID-19 policy.

article thumbnail

Direct-to-consumer advertising distorts prescription drugs’ benefits and costs

Common Sense Family Doctor

In 1998, a Letter to the Editor in American Family Physician expressed concerns about the relatively new practice of pharmaceutical advertising directly to patients. The ad states that patients may pay as little as $5 per dose, 4 times per year.… Who could blame a patient for believing the drug doesn’t cost much.

article thumbnail

FDA Safety Communications: A Potential Provider Pitfall

FDA Law

Approximately six months before the patient’s surgery, the FDA issued a Safety Communication discouraging the use of power morcellation due to the risk that the procedure could spread cancerous tissue in patients with undiagnosed uterine sarcoma. The New Jersey Punitive Damages Act (PDA) provides that “punitive damages may be awarded.